National medicines policies process world medicines situation report and access to medicines index
This presentation is the property of its rightful owner.
Sponsored Links
1 / 13

Richard Laing EMP/WHO TBS 2011 PowerPoint PPT Presentation


  • 116 Views
  • Uploaded on
  • Presentation posted in: General

National Medicines Policies Process, World Medicines Situation Report and Access to Medicines Index. Richard Laing EMP/WHO TBS 2011. Department of Essential Medicines & Pharmaceutical Policy. Objectives. Review the history of NMPs Discuss the background to NMP’s List the Components of a NMP

Download Presentation

Richard Laing EMP/WHO TBS 2011

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


National medicines policies process world medicines situation report and access to medicines index

National Medicines Policies Process, World Medicines Situation Report and Access to Medicines Index

Richard Laing EMP/WHO

TBS 2011

Department of Essential Medicines & Pharmaceutical Policy


Objectives

Objectives

  • Review the history of NMPs

  • Discuss the background to NMP’s

  • List the Components of a NMP

  • Review actors involved in the NMP process

  • Discuss the Global Pharmaceutical Market

  • Discuss the Access to Medicines Index


History of national drug policies

History of National Drug Policies

  • 1985 Nairobi Conference of Experts on rational Use of Drugs

  • 1987 Working group of Experts to draft guidelines for NDP’s

  • 1988 Guidelines for NDP’s released

  • 1995 Expert Committee on NDPs met report issued

  • 2002 New Guidelines published


Background to nmp s

Background to NMP’s

  • Need for common framework to coordinate many different actors in the pharmaceutical field:

  • These include regulators (quality, safety and efficacy), producers (local & international), users (prescribers & consumers), health planners & managers, health finance authorities and researchers.

  • Each have valid interests in the field which may be contradictory or supportive

  • Involves both public & private sectors


Components of a nmp

Components of a NMP

  • Legislation, Regulation and Guidelines

  • Selection of Drugs

  • Supply (incl. procurement & production issues)

  • Quality Assurance

  • Rational Drug Use

  • Economic Strategies for Drugs

  • Monitoring & Evaluation of NMP’s

  • Research

  • Human Resources Development

  • Technical Cooperation among Countries


Overview of components

Overview of Components

  • Each component has a crucial part in the overall policy!

  • Emphasizing one component at the expense of others, weakens the entire policy

  • Many different actors are involved. Some are outside MoH, some outside government, some outside country

  • Means that NMP planners need to be aware, though not expert, in all areas!


Characteristics of a national medicines policy

Characteristics of a National Medicines Policy

  • Essential part of health policy, must fit within the framework of a particular health care system.

  • Goals should be consistent with broader health objectives

  • Health policy and the level of service provision in a particular country are important determinants of drug policy and define the range of choices and options.

  • Implementation of an effective drug policy promotes confidence in and use of health services.


The global pharmaceutical market

The Global Pharmaceutical Market

  • Scale of Global market

    • By Value

    • By Volume

  • Generic market by Value


Distribution of total pharmaceutical expenditures by income level 2005 06

Distribution of total pharmaceutical expenditures by income level2005/06

TPE (Millions US$)

Pop (000s)

$4,123 (0.5%)

$81,235 (9.9%)

782,194 (14.4%)

983,493 (18.0%)

$76,857 (9.3%)

577,565 (10.6%)

3,106,247 (57.0%)

$660,609 (80.3%)

Data Source NHA 2005/6


Richard laing emp who tbs 2011

Source IMS Health 2008


Consumption by volume

Consumption by Volume

Volume measured by IMS Health Standard Units


2008 generic uptake after patent expiry in 2000

2008 Generic Uptake after Patent Expiry in 2000

Data Source IMS Health 2009


Richard laing emp who tbs 2011

THANK YOU


  • Login